Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers

Reuters11-06

<a href="https://laohu8.com/S/RVMD">Revolution Medicines</a> Unveils Pipeline Advancements Targeting RAS-Driven Cancers

Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS$(ON)$ inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581884707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581884707","market":"us","top_or_hot":-1,"title":"Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3f60vf:1","article_id":"2581884707","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581884707","pubTimestamp":1762378338,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS inhibitors: daraxonrasib , elironrasib , and zoldonrasib . Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma  and non-small cell lung cancer , with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor  toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc.","BK4139":"生物科技"},"translate_title":"Revolution Medicines公布针对RAS驱动癌症的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":0.9},"content_text":"Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers\n    \n\n        Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS$(ON)$ inhibitors: daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor (RMC-5127) toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581884707","isCrawlerRequest":true}